Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment

Multiple sclerosis is a biologically and clinically heterogenous inflammatory demyelinating disease, driven by relapsing and progressive mechanisms, all individuals experiencing varying degrees of both. Existing highly effective therapies target peripheral inflammation and reduce relapse rates but h...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura R. Naydovich, Jennifer L. Orthmann-Murphy, Clyde E. Markowitz
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Neurotherapeutics
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1878747925000807
Tags: Add Tag
No Tags, Be the first to tag this record!